The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA
Authors' conclusion
The discussions at the NextGen 2022 conference focused on strategies to overcome these obstacles and accelerate studies in refractory SJIA.
Study context
- Population
- Patients with refractory SJIA
Methodological detailsNextGen 2022 conference
- NextGen 2022 conference
Main finding
As reported in the abstract
- About 20% of SJIA patients continue to have active disease despite IL-1 and IL-6 inhibiting biologics
- Refractory patients are very difficult to enrol in ongoing clinical trials, given unique disease features and many background medications
Original publication
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatr Rheumatol Online J. Published 5 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →